The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorNanjing First Hospital, Nanjing Medical University

About this trial

This study is a multicenter cross-sectional research project, planning to enroll 1000 patients with Type 1 Diabetes Mellitus (T1DM). By reviewing clinical data, physical examinations, questionnaires, continuous glucose monitoring, and subcutaneous fat ultrasound, we aim to understand the current status of treatment and metabolism in Chinese T1DM patients and analyze the potential factors that may affect their blood sugar control and metabolic indicators. A cost-effectiveness analysis will be conducted on Chinese T1DM patients using continuous glucose monitoring systems to identify the groups that benefit most from these systems.

Eligibility criteria

Qualifiers

Volunteer to participate and be able to sign informed consent

Patients with type 1 diabetes

At least one of the following three clinical characteristics must be met: The disease presents initially with diabetic ketoacidosis (DKA) or ketonuria; The presence of islet-related autoantibodies, such as islet cell antibodies, tyrosine phosphatase antibodies, or glutamic acid decarboxylase (GAD) antibodies, is detected positively; Both fasting and postprandial C-peptide levels are ≤0.6 ng/mL.

Disqualifiers

Other types of diabetes.

Patients who cannot cooperate with the use of continuous glucose monitoring, clinical data collection, and questionnaire completion.

Trial design

Treatments tested in this trial

  • Continuous Glucose Monitoring System (GX-01S)

Treatment groups

1,000 Participants
are divided into 1 treatment group